Liquid Biopsy

32.2% Global CAGR for Liquid Biopsy Market to achieve US$ 358.91 Mn by 2027

Qiagen and Bio-Rad Laboratories, Inc.-Notable Market Players in Liquid Biopsy Market

Liquid biopsy is a revolutionary technology that is opening up various perspectives. The technology consists of isolation and detection of circulating tumor cells, circulating tumor DNA and exosomes, which provides genomic information of the cancer patients. Liquid biopsy are used in cancer diagnosis in order to study response or resistance to given treatments.

Market leaders operating in the market have undertaken various organic growth strategies in the liquid biopsy market. The liquid biopsy  market majorly consists of the players such as Biocept, inc., Bio-rad laboratories, inc., Lunglife ai, inc, exosome diagnostics, F. Hoffmann-la roche ltd, Inivata ltd,Exact sciences corporation, Mdxhealth, qiagen,Thermo fisher scientific inc., among others. Several organic approaches, such as product launches, and expansion/relocation in the liquid biopsy  market, have resulted in the positive growth of the market. Product launches help the company to strengthen its product offering and the customer base, which allows the company to hold a strong position in the market. Similarly, utilizing expansion activities, it is easy to venture into untapped economies and use the opportunities being offered.

Below is the list of the growth strategies done by the players operating in the liquid biopsy market:

Year

News

Mar-20

NuProbe completed Collaboration with Qiagen to develop next-generation sequencing (NGS)-based cancer diagnostic tests for non-invasive liquid biopsy

Jan-2018

Thermo Fisher Scientific has Expanded Oncomine Portfolio for Liquid Biopsy and Immuno-oncology Clinical Research. The product is adding cell-free DNA panels, this is likely to delivers Fastest Liquid Biopsy Solution to the patients.

Feb-19

Bio-Rad Received FDA approval for its liquid biopsy product namely,QXDx AutoDG ddPCR system. This product is likely to monitor molecular response to treatment among patients with chronic myeloid leukemia (CML)

March-18

Thermo Fisher Scientific and Biocept Launch Commercial Liquid Biopsy Partnership.The collaboration is likely tobegin with the companies partnering to validate Thermo Fisher’s Oncomine next-generation sequencing (NGS) liquid biopsy panels in Biocept’s CLIA-certified laboratory

 

Leave a Reply

Your email address will not be published. Required fields are marked *